Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Obstet Gynecol ; 227(6): 877.e1-877.e11, 2022 12.
Article in English | MEDLINE | ID: mdl-35863456

ABSTRACT

BACKGROUND: A total of 19 states passed legislation mandating insurance coverage of assisted reproductive technology, and out-of-pocket costs associated with in vitro fertilization vary significantly depending on the region. Consequently, it has been observed that assisted reproductive technology utilization differs regionally and is associated with the presence of an insurance mandate. However, it is unknown whether regional differences exist among patients using donor oocytes. OBJECTIVE: This study aimed to determine the patient and cycle-specific parameters associated with the use of donor oocytes according to the insurance mandate status of the Society for Assisted Reproductive Technology clinic in which the assisted reproductive technology cycle was performed. STUDY DESIGN: This study was a retrospective cohort study using national data collected from the Society for Assisted Reproductive Technology registry for 39,338 donor oocyte cycles and 242,555 autologous oocyte cycles performed in the United States from January 1, 2014, to December 31, 2016. Cycles were stratified by insurance mandate of the state in which the assisted reproductive technology cycle was performed: comprehensive (coverage for at least 4 cycles of assisted reproductive technology), limited (coverage limited to 1-3 assisted reproductive technology cycles), offer (insurance mandates exist but exclude assisted reproductive technology treatment), and no mandate. The primary outcome was the number of previous autologous assisted reproductive technology cycles of the recipient. The secondary outcomes included age, serum follicle stimulating hormone level, frozen donor oocyte utilization, day of embryo transfer, number of embryos transferred, clinical pregnancy rate, and live birth rate. Analyses were adjusted for day of transfer, number of embryos transferred, and age of the recipient. RESULTS: Patients in no mandate states underwent fewer autologous assisted reproductive technology cycles (mean, 1.1; standard deviation, 1.6) before using donor oocytes than patients in offer (mean, 1.7; standard deviation, 2.5; P<.01), limited (mean, 1.5; standard deviation, 2.5; P<.01), and comprehensive (mean, 1.7; standard deviation, 2.0; P<.01) states. Patients in no mandate states were more likely to use frozen oocytes than patients in offer (relative risk, 0.54; 95% confidence interval, 0.52-0.57), limited (relative risk, 0.50; 95% confidence interval, 0.46-0.54), and comprehensive (relative risk, 0.94; 95% confidence interval, 0.89-0.99) states. Clinical pregnancy and live birth rates were similar among recipients of donor oocytes, regardless of insurance mandate. CONCLUSION: Despite similar ages and ovarian reserve parameters, patients without state-mandated insurance coverage of assisted reproductive technology were more likely to use frozen donor oocytes and undergo fewer autologous in vitro fertilization cycles than their counterparts in partial or comprehensive insurance coverage states. These differences in donor oocyte utilization highlight the financial barriers associated with pursuing assisted reproductive technology in uninsured states.


Subject(s)
Insurance , Reproductive Techniques, Assisted , Pregnancy , Female , United States , Humans , Retrospective Studies , Pregnancy Rate , Fertilization in Vitro , Oocytes , Registries
2.
Anticancer Res ; 38(3): 1467-1470, 2018 03.
Article in English | MEDLINE | ID: mdl-29491073

ABSTRACT

AIM: To report on the unique, innovative management of a super morbidly obese patient presenting for fertility preservation in the setting of Grade 2 endometrioid endometrial adenocarcinoma. CASE REPORT: A back-to-back oocyte retrieval and robot-assisted total laparoscopic hysterectomy (RA-TLH) with bilateral salpingo-oophorectomy (BSO) was performed in a 37-year-old nulligravid woman with super morbid obesity (BMI 63 kg/m2) with endometrial cancer. MAIN OUTCOME MEASURE: the successful retrieval of oocytes for fertility preservation and oncologic intervention via RA-TLH with BSO in the same operative and anesthetic episode. RESULTS: This combined procedure strategy was successful in our case and is a feasible option for similar high-risk patients in the future. CONCLUSION: Identifying safe and effective approaches for oocyte retrieval in morbidly obese patients represents a pressing need as obesity rates rise among reproductive-aged women. Back-to-back oocyte retrieval and RA-TLH with BSO are not only feasible, but could also decrease significant anesthetic risks for morbidly obese patients.


Subject(s)
Carcinoma, Endometrioid/surgery , Endometrial Neoplasms/surgery , Hysterectomy/methods , Obesity, Morbid/surgery , Oocyte Retrieval/methods , Adult , Carcinoma, Endometrioid/complications , Endometrial Neoplasms/complications , Feasibility Studies , Female , Humans , Obesity, Morbid/complications , Oocytes/cytology , Oocytes/physiology , Robotics
3.
J Assist Reprod Genet ; 34(11): 1457-1467, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28900753

ABSTRACT

PURPOSE: The purposes of this study were to evaluate public opinion regarding fertility treatment and gamete cryopreservation for transgender individuals and identify how support varies by demographic characteristics. METHODS: This is a cross-sectional web-based survey study completed by a representative sample of 1111 US residents aged 18-75 years. Logistic regression was used to calculate odd ratios (ORs) and 95% confidence intervals (CIs) of support for/opposition to fertility treatments for transgender people by demographic characteristics, adjusting a priori for age, gender, race, and having a biological child. RESULTS: Of 1336 people recruited, 1111 (83.2%) agreed to participate, and 986 (88.7%) completed the survey. Most respondents (76.2%) agreed that "Doctors should be able to help transgender people have biological children." Atheists/agnostics were more likely to be in support (88.5%) than Christian-Protestants (72.4%; OR = 3.10, CI = 1.37-7.02), as were younger respondents, sexual minorities, those divorced/widowed, Democrats, and non-parents. Respondents who did not know a gay person (10.0%; OR = 0.20, CI = 0.09-0.42) or only knew a gay person without children (41.4%; OR = 0.29, CI = 0.17-0.50) were more often opposed than those who knew a gay parent (48.7%). No differences in gender, geography, education, or income were observed. A smaller majority of respondents supported doctors helping transgender minors preserve gametes before transitioning (60.6%) or helping transgender men carry pregnancies (60.1%). CONCLUSIONS: Most respondents who support assisted and third-party reproduction also support such interventions to help transgender people have children.


Subject(s)
Fertility Preservation/psychology , Fertility/ethics , Public Opinion , Transgender Persons/psychology , Adolescent , Adult , Aged , Cryopreservation , Female , Fertility/physiology , Fertility Preservation/ethics , Humans , Logistic Models , Male , Middle Aged , Religion , Surveys and Questionnaires
4.
J Assist Reprod Genet ; 31(5): 569-75, 2014 May.
Article in English | MEDLINE | ID: mdl-24619510

ABSTRACT

PURPOSE: To evaluate the association between serum progesterone (P) levels on the day of embryo transfer (ET) and pregnancy rates in fresh donor IVF/ICSI cycles. METHODS: Fresh donor cycles with day 3 ET from 10/2007 to 8/2012 were included (n = 229). Most cycles (93 %) were programmed with a gonadotropin releasing hormone (GnRH) agonist; oral, vaginal or transdermal estradiol was used for endometrial priming, and intramuscular P was used for luteal support (50-100 mg/day). Recipient P levels were measured at ET, and P dose was increased by 50-100 % if <20 ng/mL per clinic practice. The main outcome measure was rate of live birth (> = 24 weeks gestational age). Generalized estimating equations were used to account for multiple cycles from the same recipient, adjusted a priori for recipient and donor age. RESULTS: Mean recipient serum P at ET was 25.5 ± 10.1 ng/mL. Recipients with P < 20 ng/mL at ET, despite P dose increases after ET, were less likely to achieve clinical pregnancy (RR = 0.75, 95 % CI = 0.60-0.94, p = 0.01) and live birth (RR = 0.77, 95 % CI = 0.60-0.98, p = 0.04), as compared to those with P ≥ 20 ng/mL. P dose increases were more often required in overweight and obese recipients. CONCLUSIONS: Serum P levels on the day of ET in fresh donor IVF/ICSI cycles were positively correlated with clinical pregnancy and live birth rates. An increase in P dose after ET was insufficient to rescue pregnancy rates. Overweight and obese recipients may require higher initial doses of P supplementation. Future research is needed to define optimal serum P at ET and the interventions to achieve this target.


Subject(s)
Embryo Transfer/methods , Progesterone/administration & dosage , Progesterone/blood , Adult , Estradiol/blood , Female , Fertilization in Vitro , Humans , Maternal Age , Middle Aged , Overweight , Pregnancy , Pregnancy Rate , Tissue Donors , Treatment Outcome
5.
Fertil Steril ; 96(6): 1412-4, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22130103

ABSTRACT

OBJECTIVE: To report the results of controlled ovarian hyperstimulation (COH) after long-acting GnRH agonist (GnRH-a) and chemotherapy for the purposes of embryo cryopreservation. DESIGN: Case report. SETTING: University medical center. PATIENT(S): Two premenopausal women with acute myelogenous leukemia with recent treatment with GnRH-a and induction chemotherapy for hematopoietic cell transplantation (HCT). INTERVENTION(S): COH with embryo cryopreservation. MAIN OUTCOME MEASURE(S): Numbers of oocytes and embryos cryopreserved. RESULT(S): Both patients responded to gonadotropin stimulation and cryopreserved embryos. CONCLUSION(S): Women who have received recent long-acting GnRH-a and chemotherapy may respond to gonadotropin stimulation. The option of embryo banking can be offered to leukemia patients who are preparing for HCT.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Consolidation Chemotherapy , Embryo, Mammalian , Induction Chemotherapy , Leukemia/drug therapy , Oocyte Retrieval/methods , Tissue Banks , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Consolidation Chemotherapy/adverse effects , Female , Fertility Preservation/methods , Fertilization in Vitro , Humans , Induction Chemotherapy/adverse effects , Time Factors , Young Adult
6.
Fertil Steril ; 95(3): 1025-30, 2011 Mar 01.
Article in English | MEDLINE | ID: mdl-21122845

ABSTRACT

OBJECTIVE: To examine the association between regular physical activity and semen quality. DESIGN: Prospective cohort study. SETTING: Couples attending one of three IVF clinics in the greater Boston area during 1993-2003. At study entry, male participants completed a questionnaire about their general health, medical history, and physical activity. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived using generalized estimating equations models, accounting for potential confounders and multiple samples per man. PATIENT(S): A total of 2,261 men contributing 4,565 fresh semen samples were enrolled before undergoing their first IVF cycles. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Semen volume, sperm concentration, sperm motility, sperm morphology, and total motile sperm (TMS). RESULT(S): Overall, none of the semen parameters were materially associated with regular exercise. Compared with no regular exercise, bicycling ≥ 5 h/wk was associated with low sperm concentration (OR 1.92, 95% CI 1.03-3.56) and low TMS (OR 2.05, 95% CI 1.19-3.56). These associations did not vary appreciably by age, body mass index, or history of male factor infertility. CONCLUSION(S): Although the present study suggests no overall association between regular physical activity and semen quality, bicycling ≥ 5 h/wk was associated with lower sperm concentration and TMS.


Subject(s)
Infertility, Male/epidemiology , Infertility, Male/physiopathology , Motor Activity , Semen/cytology , Sperm Count , Sperm Motility , Adult , Bicycling , Cohort Studies , Fertilization in Vitro , Humans , Infertility, Male/therapy , Male , Prospective Studies , Risk Factors , Surveys and Questionnaires
7.
Fertil Steril ; 94(4): 1292-1295, 2010 Sep.
Article in English | MEDLINE | ID: mdl-19819435

ABSTRACT

OBJECTIVE: To determine whether oocyte donor FSH and age are independently associated IVF cycle success. DESIGN: Retrospective cohort study. SETTING: University hospital-based IVF clinic. PATIENT(S): Three hundred twelve donor/recipient pairs undergoing oocyte donation IVF. MAIN OUTCOME MEASURE(S): Number of mature oocytes and embryos, clinical pregnancy, and live birth rates. RESULT(S): Donors' basal FSH levels were not associated with IVF cycle outcomes. However, for every year increase in donor age, the number of mature oocytes decreased by 0.39 and the number of embryos decreased by 0.25 resulting in 1 less embryo for each 4-year increase in age, even in young donors. For every 100 pg/mL increase in estradiol on the day of hCG administration, the number of mature oocytes increased by 0.49 and the number of embryos increased by 0.36. For each additional 75 IU of gonadotropin used during stimulation, the likelihood of pregnancy and live birth decreased by 3.5%. CONCLUSION(S): Donor oocyte IVF cycle outcomes were not associated with donor basal FSH. However, donor age and estradiol level on the day of hCG administration were significantly associated with numbers of mature oocytes and embryos obtained, and the amount of gonadotropin used in the stimulation was significantly associated with the likelihood of pregnancy and live birth.


Subject(s)
Fertilization in Vitro , Follicle Stimulating Hormone/blood , Oocyte Donation , Tissue Donors , Adult , Age Factors , Chorionic Gonadotropin/administration & dosage , Dose-Response Relationship, Drug , Estradiol/blood , Female , Fertility Agents, Female/administration & dosage , Humans , Multivariate Analysis , Oocyte Donation/methods , Ovulation/blood , Ovulation Induction/methods , Pregnancy , Pregnancy Rate , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...